Ibrutinib combination regimens for CLL from ASH 2017
Description: Despite the combination of ibrutinib and rituximab not significantly affecting progression-free survival in patients with chronic lymphocytic leukemia (CLL), many groups are testing ibrutinib combination regimens. Here, Jacqueline Barrientos, MD, of the Feinstein Institute for Medical Research, Manhasset, NY, discusses the results of ibrutinib combinations for CLL that were presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Dr Barrientos highlights the combination of ibrutinib with obinutuzumab and venetoclax. She also explains how she thinks ibrutinib combination therapy for CLL will be utilized in the future and why good ibrutinib combinations are so highly desired. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/08/18
Added : 6 months ago